Temporal Trends in Humoral and Cellular Immune Responses to Sars-Cov-2 mRNA Vaccines Among Multiple Sclerosis Patients Treated with Natalizumab, Ocrelizumab or Fumarates
Background: Vaccines against SARS-CoV-2 are a key component of public health measures to combat the COVID-19 pandemic. The impact of...